Conference Call with Mankind Pharma Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Mankind Pharma announced Q1FY26 results Revenue from Operations at Rs 3,570 crore, up by 24.5% YoY. Domestic revenue at Rs 3,101 crore, up 18.9%, Exports at Rs 469 crore, up 81.1% YoY. EBITDA margin of 23.8% up by 20 bps YoY and PAT margin of 12.5%. Diluted EPS of Rs 10.6 down by 20.1% YoY (FV Re 1). Rajeev Juneja, Vice Chairman & Managing Director, said: “Mankind’s revenue grew by 24.5% with EBITDA margins at 23.8% in Q1FY26 led by continued 1.4x outperformance in Chronic, strong growth in Consumer segment and BSV consolidation. Visible encouraging trends with 1.8x volume growth to IPM led by outperformance in Anti-infectives & Respiratory segment – apart from continued outperformance in Cardiology and Anti Diabetics. BSV growth initiatives are making steady progress and we remain confident of delivering healthy performance this year onwards. As we celebrate 30 years of our operations, we would like our shareholders to be part of this milestone therefore the Company’s Board has approved an interim dividend of Rs 1 per share.” Result PDF